Viking’s heart bypass

Viking navigates thyroid receptor β agonist tissue specificity for X-ALD

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214, cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy (X-ALD). The company thinks VK0214’s cardiac-sidestepping chemistry is a good match for the disease and a safeguard against the heart toxicity that has made

Read the full 582 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE